Search

Antibody Drug Conjugates with Amatoxin Derivatives for Cancer Treatment

Vivasor, Inc. has been granted European Patent EP3471771A1 covering antibody drug conjugates using amatoxin derivatives as cytotoxic payloads for the treatment of cancer, with publication occurring on 15 April 2026. The patent application EP3471771 claims priority based on earlier filings and lists four named inventors: ZHU Tong, ZHANG Hong, KHASANOV Alisher, and CHEN Gang. The designation covers 32 European contracting states including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Sweden, and others.